Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer. Farmeconomia. Health economics and therapeutic pathways, [S. l.], v. 7, n. 2, p. 97–117, 2006. DOI: 10.7175/fe.v7i2.680. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/680. Acesso em: 29 oct. 2025.